MAT2A is a synthetic lethal target in cancers with genomic deletion of methylthioadenosine phosphorylase (MTAP)21–24, and was shown to be a metabolic vulnerability of tumour-initiating cells in lung cancer21–25. Here, MTAP is linked to cancer.